Technical Analysis for FGEN - Fibrogen Inc CS

Grade Last Price % Change Price Change
grade C 42.94 1.35% 0.5700
FGEN closed up 1.35 percent on Tuesday, January 21, 2020, on approximately normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical FGEN trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Gapped Up Strength 1.35%
New 52 Week Closing Low Bearish 13.60%
Hot IPO Pullback Bullish Swing Setup 13.60%
New 52 Week Low Weakness 13.60%
Gapped Down Weakness 13.60%
New 52 Week Closing Low Bearish 5.92%
New 52 Week Low Weakness 5.92%
Gapped Down Weakness 5.92%
Older signals for FGEN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
RTT Biopharmaceutical Chronic Kidney Disease Pancreatic Cancer Anemia Proteins Astrazeneca China Idiopathic Pulmonary Fibrosis Muscular Dystrophy Myelodysplastic Syndrome Enzymes Liver Fibrosis Catalysts Myelodysplastic Syndromes Acetic Acids Corneal Blindness Hypoxia Inducible Factors Treatment Of Idiopathic Pulmonary Fibrosis

Is FGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 45.9095
52 Week Low 37.34
Average Volume 560,417
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0000
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.4750
Resistance 3 (R3) 45.5633 44.8067 45.0525
Resistance 2 (R2) 44.8067 44.1611 44.7625 44.9116
Resistance 1 (R1) 43.8733 43.7622 43.4950 43.7850 44.7708
Pivot Point 43.1167 43.1167 42.9275 43.0725 43.1167
Support 1 (S1) 42.1833 42.4711 41.8050 42.0950 41.1092
Support 2 (S2) 41.4267 42.0722 41.3825 40.9684
Support 3 (S3) 40.4933 41.4267 40.8275
Support 4 (S4) 40.4050